NZ230041A - Selectively o-acylated glycosaminoglycans; their preparation and pharmaceutical compositions containing them - Google Patents

Selectively o-acylated glycosaminoglycans; their preparation and pharmaceutical compositions containing them

Info

Publication number
NZ230041A
NZ230041A NZ230041A NZ23004189A NZ230041A NZ 230041 A NZ230041 A NZ 230041A NZ 230041 A NZ230041 A NZ 230041A NZ 23004189 A NZ23004189 A NZ 23004189A NZ 230041 A NZ230041 A NZ 230041A
Authority
NZ
New Zealand
Prior art keywords
selectively
preparation
pharmaceutical compositions
compositions containing
glycosaminoglycans
Prior art date
Application number
NZ230041A
Inventor
Maurice Petitou
Jean-Claude Lormeau
Jean Choay
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of NZ230041A publication Critical patent/NZ230041A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0069—Chondroitin-4-sulfate, i.e. chondroitin sulfate A; Dermatan sulfate, i.e. chondroitin sulfate B or beta-heparin; Chondroitin-6-sulfate, i.e. chondroitin sulfate C; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrrole Compounds (AREA)

Abstract

The glycosaminoglycans of the invention are selectively O-acylated in a controllable manner on their free -OH groups, the carboxylic or amino functional groups being unaltered. These compounds have a pharmacological activity of very long duration.
NZ230041A 1988-07-21 1989-07-21 Selectively o-acylated glycosaminoglycans; their preparation and pharmaceutical compositions containing them NZ230041A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8809885A FR2634485B1 (en) 1988-07-21 1988-07-21 SELECTIVELY O-ACYLATED GLYCOSAMINOGLYCANS, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Publications (1)

Publication Number Publication Date
NZ230041A true NZ230041A (en) 1991-09-25

Family

ID=9368648

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ230041A NZ230041A (en) 1988-07-21 1989-07-21 Selectively o-acylated glycosaminoglycans; their preparation and pharmaceutical compositions containing them

Country Status (23)

Country Link
EP (1) EP0356275B1 (en)
JP (1) JPH0273801A (en)
KR (1) KR910002889A (en)
AT (1) ATE108804T1 (en)
AU (1) AU620632B2 (en)
DD (1) DD285606A5 (en)
DE (1) DE68916878T2 (en)
DK (1) DK362789A (en)
ES (1) ES2056239T3 (en)
FI (1) FI893518A (en)
FR (1) FR2634485B1 (en)
HU (1) HU206222B (en)
IE (1) IE892367L (en)
IL (1) IL91058A0 (en)
MA (1) MA21602A1 (en)
NO (1) NO892986L (en)
NZ (1) NZ230041A (en)
OA (1) OA09125A (en)
PT (1) PT91249B (en)
RU (1) RU1831487C (en)
TN (1) TNSN89082A1 (en)
YU (1) YU172789A (en)
ZA (1) ZA895581B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5550116A (en) * 1990-12-03 1996-08-27 Sanofi N,O-sulphated heparosans and pharmaceutical compositions containing them

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834444A (en) * 1991-07-03 1998-11-10 Hyal Pharmaceutical Corporation Hyaluronic acid and salts thereof inhibit arterial restenosis
US5990095A (en) 1991-07-03 1999-11-23 Hyal Pharmaceutical Corporation Use of hyaluronic acid and forms to prevent arterial restenosis
US5498775A (en) * 1994-11-07 1996-03-12 American Home Products Corporation Polyanionic benzylglycosides as inhibitors of smooth muscle cell proliferation
IL115745A (en) * 1994-11-07 2000-11-21 American Home Prod Acylated benzylglycosides and pharmaceutical compositions containing them
US5565432A (en) * 1994-11-07 1996-10-15 American Home Products Corporation Smooth muscle cell proliferation inhibitors
IT1286510B1 (en) * 1996-11-29 1998-07-15 Cooperativa Centro Ricerche Po BUTYRIC ESTERS WITH ANTI-PROLIFERATIVE ACTIVITY AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
US7081448B2 (en) 1998-11-24 2006-07-25 Wyeth Benzyllactobionamides as inhibitors of smooth muscle cell proliferation
US6664243B1 (en) 1998-11-24 2003-12-16 Wyeth Benzyllactobionamides as inhibitors of smooth muscle cell proliferation
US6362170B1 (en) 1998-11-24 2002-03-26 American Home Products Corporation Benzylglycosylamides as inhibitors of smooth muscle cell proliferation
US6339064B1 (en) 1998-11-24 2002-01-15 American Home Products Corporation Benzylglycosylamides as inhibitors of smooth muscle cell proliferation
US6258784B1 (en) 1998-11-24 2001-07-10 American Home Products Corp. Acetal benzylmaltosides as inhibitors of smooth muscle cell proliferation
US7132402B2 (en) 1998-11-24 2006-11-07 Wyeth Acylated benzylmaltosides as inhibitors of smooth muscle cell proliferation
US6340670B1 (en) 1998-11-24 2002-01-22 American Home Products Corporation Acetal benzylmaltosides as inhibitors of smooth muscle cell proliferation
CA2317305A1 (en) 2000-08-29 2002-02-28 Tassos P. Anastassiades Method of enhancing chondrocyte cell growth and glycosaminoglycan production
KR20030057040A (en) * 2001-12-28 2003-07-04 주식회사 효성 D-Glucosamine derivatives and Method for Preparing Thereof
KR100790007B1 (en) * 2006-12-28 2008-01-02 경상대학교산학협력단 A method for purification glycosaminoglycans from ascidian tunic
CN103209997B (en) * 2010-09-14 2016-03-16 国立大学法人宫崎大学 high-purity heparin and preparation method thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3066M (en) * 1963-08-07 1965-01-18 Roussel Uclaf New drug, in particular for the treatment of postprandial or chronic hyperlipemia.
JPS469327B1 (en) * 1966-03-31 1971-03-09
JPS52111983A (en) * 1976-03-18 1977-09-20 Teijin Ltd Preparation of heparin derivatives
US4331697A (en) * 1980-09-02 1982-05-25 Teijin Limited Novel heparin derivative, method for production thereof, and method for rendering biomedical materials antithrombotic by use of the novel heparin derivative
FR2584728B1 (en) * 1985-07-12 1987-11-20 Choay Sa PROCESS FOR THE SULFATION OF GLYCOSAMINOGLYCANS AND THEIR FRAGMENTS
JP5410580B1 (en) * 2012-08-09 2014-02-05 日本特殊陶業株式会社 Wiring board

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5550116A (en) * 1990-12-03 1996-08-27 Sanofi N,O-sulphated heparosans and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
DE68916878D1 (en) 1994-08-25
DK362789D0 (en) 1989-07-21
DD285606A5 (en) 1990-12-19
AU620632B2 (en) 1992-02-20
IE892367L (en) 1990-01-21
AU3885689A (en) 1990-01-25
MA21602A1 (en) 1990-04-01
HU206222B (en) 1992-09-28
EP0356275A1 (en) 1990-02-28
ATE108804T1 (en) 1994-08-15
RU1831487C (en) 1993-07-30
IL91058A0 (en) 1990-02-09
FI893518A0 (en) 1989-07-21
OA09125A (en) 1991-10-31
FR2634485B1 (en) 1992-02-28
YU172789A (en) 1991-08-31
DK362789A (en) 1990-01-22
FI893518A (en) 1990-01-22
NO892986L (en) 1990-01-22
ES2056239T3 (en) 1994-10-01
PT91249B (en) 1995-05-04
DE68916878T2 (en) 1995-03-16
KR910002889A (en) 1991-02-26
JPH0273801A (en) 1990-03-13
HUT50489A (en) 1990-02-28
TNSN89082A1 (en) 1991-02-04
ZA895581B (en) 1990-04-25
EP0356275B1 (en) 1994-07-20
PT91249A (en) 1990-02-08
NO892986D0 (en) 1989-07-20
FR2634485A1 (en) 1990-01-26

Similar Documents

Publication Publication Date Title
NZ230041A (en) Selectively o-acylated glycosaminoglycans; their preparation and pharmaceutical compositions containing them
GR3015232T3 (en) Angioplasty apparatus.
IL92377A0 (en) Quinuclidines,their preparation and pharmaceutical compositions comprising them
IL89881A0 (en) Peptide derivatives,their production and pharmaceutical compositions containing them
NZ238288A (en) Pyrazolo- and triazolo-(1,3,5)triazine derivatives; processes and pharmaceutical compositions
NZ225117A (en) Trans -2,2-dimethylchroman-3-ol derivatives and pharmaceutical compositions
IL89192A0 (en) Pharmaceutical compositions containing lactams,substituted lactams and processes for the preparation thereof
IL89752A0 (en) Bisphosphonates,their production and pharmaceutical compositions containing them
ZA891696B (en) Pyrimidinyl-substituted hydroxyacids,lactones and esters and pharmaceutical compositions containing them
DK170889A (en) 9-Halogen-prostane derivatives, and medicaments which comprise them
IL89504A0 (en) Diphtheria toxin derivative,process for the preparation thereof and pharmaceutical composition containing the same
IL88927A0 (en) Thienoazepines,their production and pharmaceutical compositions containing them
NZ226516A (en) 2,2 dimethylchromene derivatives and pharmaceutical compositions
NZ221059A (en) Cycloalkyl substituted 4-pyridyl derivatives, pharmaceutical compositions and preparations
NZ234578A (en) 2-oxo-1,2-dihydropyridine derivatives and pharmaceutical compositions
IL99294A0 (en) Indolonaphthyridines,their production and pharmaceutical compositions containing them
NZ227235A (en) Substituted 1,5-benzothiazepin-4-one derivatives and pharmaceutical compositions
NZ227880A (en) Pyridyl substituted 1,3 dioxane alkenoic acid derivatives and pharmaceutical compositions
NZ221542A (en) (4,2,0) bicyclooctane derivatives and pharmaceutical compositions
IL88673A0 (en) N-hydroxy-5-phenyl-2-furancarboxi-midamides,and pharmaceutical compositions containing them
GB2200629B (en) A substituted 1,2,3,4-tetrahydropyrimidine having coronary dilating activity,and pharmaceutical compositions thereof
NZ224728A (en) 3-acylaminomethyl-5,6,7,8-tetrahyd-pyridine derivatives and pharmaceutical compositions
GR3005838T3 (en)
IL89897A0 (en) Peptide derivatives,their production and pharmaceutical compositions containing them
IL82100A0 (en) Pharmaceutical composition containing 2,4,6-tris-tertiary-butyl-amino-1,3,5-triazine